NVO vs PFE
Novo Nordisk A/S and Pfizer, both Healthcare
Novo Nordisk A/S is the larger company at $171B against $162B. Over the past year PFE returned +24% against -34% for NVO. The RyuScore puts NVO ahead, 88 against 60 out of 100.
| Figure | NVO | PFE |
|---|---|---|
| Last close | $38.58 | $28.42 |
| Market cap | $171B | $162B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 37.4 |
| Dividend yield | n/a | 6.1% |
| 1-year return | -34% | +24% |
| 5-year return | -16% | -19% |
| RyuScoresector-relative, 1–10 | 88/100 | 60/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Novo Nordisk A/S
Pfizer
Revenue of $15B in Q2 2026, net income null. Its largest reported line is Eliquis, 16% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.